On June 27, 2022, ESSA Pharma, Inc. EPIX provided an update on the company's Phase 1 clinical trial of EPI-7386 in patients with mCRPC who had progressed on two or more systemic therapies, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results